Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells

Molecular Cancer Research

Volumn 9, Issue 8, 2011, Pages 1152-1162

  Mian, Omar Y ^a,c   Wang, Shou Zhen ^a   Zhu, Sheng Zu ^a   Gnanapragasam, Merlin N ^a,c   Graham, Laura ^a   Bear, Harry D ^a,b,c   Ginder, Gordon D ^a,b,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; METHYL CPG BINDING PROTEIN; METHYL CYTOSINE BINDING DOMAIN PROTEIN 2; PROTEIN DAPK1; PROTEIN KLK10; SHORT HAIRPIN RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CPG ISLAND; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CPG ISLANDS; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM STAGING; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

MUS;

EID: 80051967782     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-11-0252     Document Type: Article

References (53)

1. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-1159
2. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007;128:683-692 (Pubitemid 46273572)
3. Taby R., Issa J.P. Cancer epigenetics. CA Cancer J Clin 2010;60:376-392
4. Grant S. Targeting histone demethylases in cancer therapy. Clin Cancer Res 2009;15:7111-7113
5. Jabbour E., Issa J.P., Garcia-Manero G., Kantarjian H. Evolution of decitabine development: Accomplishments, ongoing investigations, and future strategies. Cancer 2008 [cited 10/4/2008];112:2341-51.
6. Appleton K., Mackay H.J., Judson I., Plumb J.A., McCormick C., Strathdee G., et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007;25:4603-4609 (Pubitemid 350035319)
7. Oki Y., Issa JP. Review: Recent clinical trials in epigenetic therapy. Rev Recent Clin Trials 2006 [cited 10/4/2008];1:169-82.
8. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., et al. Induction of tumors in mice by genomic hypomethylation. Science 2003;300:489-492 (Pubitemid 36444330)
9. Klose R.J., Bird A.P. Genomic DNA methylation: The mark and its mediators. Trends Biochem Sci 2006;31:89-97. (Pubitemid 43221841)
10. Ballestar E., Esteller M. Methyl-CpG-binding proteins in cancer: Blaming the DNA methylation messenger. Biochem Cell Biol 2005;83:374-384 (Pubitemid 41297205)
11. Hendrich B., Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 1998;18:6538-6547 (Pubitemid 28500543)
12. Prokhortchouk A., Hendrich B., Jorgensen H., et al. The p120 catenin partner kaiso is a DNA methylation-dependent transcriptional repressor. Genes Dev 2001;15:1613-1618 (Pubitemid 32702582)
13. Lopez-Serra L., Ballestar E., Ropero S., Setien F., Billard L.M., Fraga M.F., et al. Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins. Oncogene 2008.
14. Berger J., Bird A. Role of MBD2 in gene regulation and tumorigenesis. Biochem Soc Trans 2005;33:1537-1540 (Pubitemid 41779733)
15. Fraga M.F., Ballestar E., Montoya G., Taysavang P., Wade P.A., Esteller M. The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res 2003;31:1765-1774 (Pubitemid 36336578)
16. Sansom O.J., Berger J., Bishop S.M., Hendrich B., Bird A., Clarke A.R. Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat Genet 2003;34:145-147 (Pubitemid 36666922)
17. Hendrich B., Guy J., Ramsahoye B., Wilson V.A., Bird A. Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev 2001;15:710-723 (Pubitemid 32244900)
18. Sansom O.J., Maddison K., Clarke A.R. Mechanisms of disease: Methyl-binding domain proteins as potential therapeutic targets in cancer. Nat Clin Pract Oncol 2007;4:305-315 (Pubitemid 46758788)
19. Corn P.G. Methylation marks the path for biomarker development in breast cancer research. Cancer Biol Ther 2009;8.
20. Futscher B.W., O'Meara M.M., Kim C.J., Rennels M.A., Lu D., Gruman L.M., et al. Aberrant methylation of the maspin promoter is an early event in human breast cancer. Neoplasia 2004;6:380-389 (Pubitemid 38924853)
21. Honorio S., Agathanggelou A., Schuermann M., et al. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 2003;22:147-150 (Pubitemid 36152892)
22. Lustberg M.B., Ramaswamy B. Epigenetic targeting in breast cancer: Therapeutic impact and future direction. Drug News Perspect 2009;22:369-381
23. Wiznerowicz M., Trono D. Conditional suppression of cellular genes: Lentivirus vector-mediated drug-inducible RNA interference. J Virol 2003;77:8951-8957
24. Choi J.K., Hoang N., Vilardi A.M., Conrad P., Emerson S.G., Gewirtz A.M. Hybrid HIV/MSCV LTR enhances transgene expression of lentiviral vectors in human CD34(+) hematopoietic cells. Stem Cells 2001;19:236-246 (Pubitemid 32524544)
25. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827-4833
26. Barrett D.M., Gustafson K.S., Wang J., Wang S.Z., Ginder GD. A GATA factor mediates cell type-restricted induction of HLA-E gene transcription by gamma interferon. Mol Cell Biol 2004;24:6194-6204 (Pubitemid 38891122)
27. Rupon J.W., Wang S.Z., Gaensler K., Lloyd J., Ginder G.D. Methyl binding domain protein 2 mediates gamma-globin gene silencing in adult human beta YAC transgenic mice. Proc Natl Acad Sci U S A 2006;103:6617-6622
28. Cui W., Taub D.D., Gardner K. qPrimerDepot: A primer database for quantitative real time PCR. Nucleic Acids Res 2007;35:D805-D809 (Pubitemid 46056313)
29. Welch D.R. Technical considerations for studying cancer metastasis in vivo. Clin Exp Metastasis 1997;15:272-306. (Pubitemid 27240358)
30. Klerk C.P., Overmeer R.M., Niers T.M., Versteeg H.H., Richel D.J., Buckle T., et al. Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. BioTechniques 2007;43:7, 13, 30.
31. Kransdorf E.P., Wang S.Z., Zhu S.Z., Langston T.B., Rupon J.W., Ginder G.D. MBD2 is a critical component of a methyl cytosine-binding protein complex isolated from primary erythroid cells. Blood 2006;108:2836-2845
32. Lopez-Serra L., Ballestar E., Fraga M.F., Alaminos M., Setien F., Esteller M. A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human cancer. Cancer Res 2006;66:8342-8346 (Pubitemid 44449141)
33. Muggerud A.A., Rønneberg J.A., Wärnberg F., Botling J., Busato F., Jovanovic J., et al. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res 2010;12:R3.
34. Dumont N., Crawford Y.G., Sigaroudinia M., Nagrani S.S., Wilson M.B., Buehring G.C., et al. Human mammary cancer progression model recapitulates methylation events associated with breast premalignancy. Breast Cancer Res 2009;11:R87.
35. Hoque M.O., Prencipe M., Poeta M.L., et al. Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev 2009;18:2694-2700
36. Hendrich B., Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 1998;18:6538-6547 (Pubitemid 28500543)
37. Zhang Y., Ng H.H., Erdjument-Bromage H., Tempst P., Bird A., Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev 1999;13:1924-1935 (Pubitemid 29407360)
38. Gnanapragasam M.N., Scarsdale J.N., Amaya M.L., Webb H.D., Desai M.A., Walavalkar N.M., et al. p66{alpha}-MBD2 coiled-coil interaction and recruitment of mi-2 are critical for globin gene silencing by the MBD2-NuRD complex. Proc Natl Acad Sci U S A 2011.
39. Sproul D., Nestor C., Culley J., Dickson J.H., Dixon J.M., Harrison D.J., et al. Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proc Natl Acad Sci U S A 2011;108:4364-4369
40. Si J., Boumber Y.A., Shu J., Qin T., Ahmed S., He R., et al. Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Res 2010;70:6968-6977
41. Ballestar E. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 2003;22:6335-6345 (Pubitemid 37522590)
42. Scarsdale J.N., Webb H.D., Ginder G.D., Williams D.C. Jr. Solution structure and dynamic analysis of chicken MBD2 methyl binding domain bound to a target-methylated DNA sequence. Nucleic Acids Res 2011.
43. Park I.H., Zhao R., West J.A., et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008;451:141-146
44. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872 (Pubitemid 350138099)
45. Martin V., Jørgensen H.F., Chaubert A.S., Berger J., Barr H., Shaw P., et al. MBD2-mediated transcriptional repression of the p14ARF tumor suppressor gene in human colon cancer cells. Pathobiology 2008;75:281-287
46. Pulukuri S.M., Rao J.S. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2. Oncogene 2006;25:4559-4572 (Pubitemid 44175115)
47. Issa J.P. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 2010;24:317-330
48. Tsai H.C., Baylin S.B. Cancer epigenetics: Linking basic biology to clinical medicine. Cell Res 2011;21:502-517
49. Eckhardt F., Lewin J., Cortese R., Rakyan V.K., Attwood J., Burger M., et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 2006;38:1378-1385 (Pubitemid 44837559)
50. Suzuki M.M., Bird A. DNA methylation landscapes: Provocative insights from epigenomics. Nat Rev Genet 2008;9:465-476 (Pubitemid 351693975)
51. Martin Caballero I., Hansen J., Leaford D., Pollard S., Hendrich B.D. The methyl-CpG binding proteins Mecp2, Mbd2 and kaiso are dispensable for mouse embryogenesis, but play a redundant function in neural differentiation. PLoS One 2009;4:e4315.
52. Sansom O.J., Maddison K., Clarke A.R. Mechanisms of disease: Methyl-binding domain proteins as potential therapeutic targets in cancer. Nat Clin Pract Oncol 2007;4:305-315 (Pubitemid 46758788)
53. Sansom O.J., Bishop S.M., Bird A., Clarke A.R. MBD2 deficiency does not accelerate p53 mediated lymphomagenesis. Oncogene 2005;24:2430-2432 (Pubitemid 40546701)